key: cord-0335807-9804dls6
authors: Huzly, D.; Panning, M.; Smely, F.; Enders, M.; Komp, J.; Steinmann, D.
title: Validation and performance evaluation of a novel interferon-γ release assay for the detection of SARS-CoV-2 specific T-cell response
date: 2021-07-22
journal: nan
DOI: 10.1101/2021.07.17.21260316
sha: 9afd4941feb8cbdf72c210224d7b826a7f3cd88f
doc_id: 335807
cord_uid: 9804dls6

Background: The reliable detection of the T-cell mediated response to COVID-19 or COVID-19 vaccination is important for individual patient care and for monitoring the immune response e.g. in COVID-19 vaccine trials in a standardized fashion. Methods: We used blood samples from health care workers (HCW) with or without history of COVID-19 to define test accuracy of a novel interferon-{gamma} release assay. Usefulness of qualitative and quantitative results after COVID-19 vaccination was examined in HCW receiving homologous or heterologous vaccination regimens. For a real-life performance evaluation, we analysed interferon-{gamma} response to complete vaccination in 149 patients receiving immunosuppressive or immune modulating therapies. Results: Using a double-cut-off strategy integrating the result of background stimulation the assay had a specificity of 100%. Sensitivity of the IGRA was 83.5 and 100% in HCW after SARS-CoV-2 infection more or less than 6 months ago. Quantitative results showed significant differences between first and second vaccine dose, but no difference between homologous and heterologous vaccination regimen. The majority of immunocompromised patients showed no immune response or isolated T-cell or antibody response to complete vaccination. Conclusions: The novel IGRA proved to be a highly specific and sensitive tool to detect the SARS-CoV-2 specific T-cell response to COVID-19 as well as COVID-19 vaccination. In perspective, it may serve as a standardized tool in COVID-19 vaccine trials and in clinical care of immunosuppressed patients.

The role of the T-cell immune response in SARS-CoV-2 infection is not entirely understood, but data 56 from animal models show an important role for protection against coronavirus disease 2019 (COVID-57 19) mediated by CD4 + and CD8 + T cells and the production of interferon gamma (IFN-) [1, 2]. Since 58

December 2020, the first vaccines against COVID-19 are available but the quality and duration of the 59 immune response to vaccination remains unclear as of yet. Although numerous SARS-CoV-2 antibody 60 detection assays were introduced with unprecedented speed and are now widely in use, the 61 implementation of T cell assays lagged behind. However, besides analysing the antibody response, it 62 will be of importance to investigate the T-cell mediated immune response, e.g. in vaccine trials or in a 63 clinical setting for individual patient care. Therefore, easy to perform, validated, and ideally 64

standardized T-cell assays are required [3] . 65 66

Here we evaluated a novel commercially available IFN- release assay (IGRA) to analyse the SARS-CoV-67 2 specific T-cell response. IGRA have revolutionized the diagnosis of tuberculosis [4] and several other 68 pathogens [5, 6] . In experimental settings, in-house SARS-CoV-2 IGRA were introduced recently [7]. 69

The main advantage of this type of assay is the possibility to perform them without special equipment 70 and with very short hands-on time. The IFN- results are expressed in international units and are 71 therefore truly quantitative. 72 73 For our evaluation study, we asked immunocompetent healthcare workers (HCW) at Freiburg 74 University Hospital to participate and offered measurement of SARS-CoV-2 antibodies. One group 75 comprised HCW who had experienced mild SARS-CoV-2 infection in 2020 and another group had been 76 vaccinated against COVID-19. For negative controls, we asked HCW without a history of COVID-19 prior 77 to vaccination. After successful evaluation of the assay, we analysed the COVID-19 vaccine associated 78 T-cell immune response in several patient groups including immunocompromised patients to evaluate 79 the test performance in a real-life setting. 80 81 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were reactive in several antibody assays against SARS-CoV-2 nucleoprotein (N) and spike protein (S1) 146 (Table 2) , suggesting past infection. Thus, we excluded these samples from further analysis. Serum 147 samples from the 52 remaining individuals of this cohort tested negative with three different SARS-148

CoV-2 antibody assays and were therefore defined as truly negative controls. Specificity of the assay 149 using 200 mIU/ml and 100 mIU/ml was 100% [95% confidence interval (CI) 93.2%-100%] and 96.2% 150 (95% CI 86.8%-99.5%), respectively. 151

Highest Youden index using ROC analysis was seen at 135 mIU/ml with a specificity of 98.1% (95% CI 152 89.8%-99.9%). We therefore re-analysed data using three different cut-offs with IFN- concentrations 153 of 100 mIU/ml, 135 mIU/ml, and 200 mIU/ml. 154

A total of 107 samples from HCW with previous SARS-CoV-2 infection were available to us. In one case, 156 the assay was invalid and thus excluded from the analysis. Of these, 90 HCW had blood samples drawn 157 more than six months after RT-PCR proven SARS-CoV-2 infection. Eleven (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.17.21260316 doi: medRxiv preprint 7 taken more than 6 months ago. Another 16 individuals were infected two to five months ago, 15 of 162 which had IFN- concentrations above 200 mIU/ml and one was in our calculated as well as in the 163 manufacturers grey-zone (151 mIU/ml). Sensitivity for recent infection in this subgroup was thus 93.8% 164 or 100% defining grey-zone results as positive. Overall sensitivity to detect past infection using 165 different cut-offs was 75.4%, 89.6% and 88.7% with cut-off 200 mIU/ml, 100 mIU/ml or 135 mIU/ml, 166 respectively. 167

In the initial validation, BLANK values were below 50 mIU/ml (mean 35.2 mIU/ml, range 0-1520 169 mIU/ml) in most patients, but 23/230 (10%) showed elevated IFN- concentrations above 100 mIU/ml 170 including the two false positive samples (see above). We therefore aimed to include the BLANK values 171 into the result interpretation and to circumvent the need of a grey-zone. Subsequently, we used a cut-172 off of equal or above 135 mIU/ml in individuals with background stimulation below 100 mIU/ml and a 173 cut-off of 200 mIU/ml in individuals with higher background stimulation. Using our BLANK value 174 adapted approach the specificity reached 100 % and overall sensitivity to detect past infection was 175 86.8% (Table 3 ). In detail, it was 100% for infection less than five months ago and 83.5% for infection 176 more than 6 months ago. Predictive values and accuracy of the different cut-off strategies are shown 177 in Table 3 . Of note, 20 out of 107 (18.7%) HCW several months after SARS-CoV-2 infection were 178 negative for SARS-CoV-2 S1-IgG but tested positive for IFN- stimulation using the BLANK value 179 adapted cut-off. Three of five HCW who were non-reactive even in the highly sensitive total-antibody 180 assays were positive showing IFN- concentrations between 136 and 630 mIU/ml. In nine of 11 cases 181 with equivocal SARS-CoV-2 S1-IgG, IFN- results were positive. 182

Next, we analysed IFN- concentrations in HCW after COVID-19 vaccination. In the BNT162b2 group, 184 36/38 (95%) had IFN- concentrations above 200 mIU/ml after the first dose and 38/38 (100%) after 185 the second dose, respectively ( Figure 1 ). Of note, two participants had no IFN- release after the first 186 vaccination (6 and 9 mIU/ml), but subsequently reacted after the second dose of BNT162b2. In 187 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Median IFN- concentration was significantly different between individuals with past infection more 193 than 6 months vs. less than 6 months ago (Mann-Whitney U test, p=0.001) (Figure 1 ). concentrations after first dose of BNT162b2 vaccine were similar as those after recent infection and 195 significantly lower than concentrations after the second dose (Wilcoxon test, p=0.0010). Median  concentration after the first dose of AZD1222 was higher than after the first dose of BNT162B2 with 197 a large range (Mann-Whitney U test, p=0.04). Median concentration after heterologous booster 198 immunization with mRNA1273 was similar to median concentration after second dose with BNT162b2. 199 Mean, median, standard deviation and range are shown in Table 4 . In the HCW group with past 200 infection more than 6 months ago median IFN- concentration was significantly higher in individuals 201 older than 50 years than in younger individuals (Mann-Whitney U test, p<0.0001). There was no 202 significant difference between age groups in vaccinated HCW or in those who had experienced the 203 infection less than 6 months ago. 204

After validation and implementation of the assay in our routine diagnostic lab, we encouraged 206 colleagues to analyse the immune response in immunocompromised patients after complete COVID-207 19 vaccination. These patients (n=149) had various underlying diseases and received 208 immunosuppressive or immune modulating therapies or had variable immunodeficiency (Table 5 ). The 209 majority of immunocompromised patients showed an inadequate immune response to vaccination, 210 which was in most cases done using BNT162b2 and in few cases applying the heterologous vaccination 211 scheme AZD1222/BNT162b2. Of note, most responding patients had isolated T-cell or antibody 212 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.17.21260316 doi: medRxiv preprint response ( Table 5) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. thoroughly. The IGRA proved to be a sensitive and specific tool for detecting the cellular immune 243 response to COVID-19 or COVID-19 vaccination. Technically, it is easy to perform and can be rapidly 244 implemented in routine diagnostic laboratories. This will assist e.g. in patient care and future COVID-245 19 vaccination trials as it will allow on site testing of the cellular immune response using standardized 246 and widely available assays. 19 vaccination seem not to be affected by mutations found in SARS-CoV-2 variants of concern [25-28], 263 whereas neutralizing capacity of antibodies is significantly reduced [29] . It is therefore of importance 264 to measure T-cell mediated reactivity to evaluate immune response to vaccination. 265 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. based testing alone, as antibodies wane after several months and in some cases become undetectable 286 even with the most sensitive antibody assays [16] . Highly specific T-cell assays may help proving 287 specificity of low positive or grey-zone antibody results. In a recent study with COVID-19 convalescents, 288 a cellular immune response had been detectable in 78% of non-seroconverting and 80% of 289 seroconverting patients by ELISPOT using different peptide pools and proteins. The authors found 290 highest specificity but lowest sensitivity using the S1 protein [18] . The EUROIMMUN IGRA uses only an 291 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.17.21260316 doi: medRxiv preprint S1 peptide pool for stimulation; however, using the adapted cut-off specific IFN-y release was detected 292 in 100% and 83.5% of individuals after infection less and more than 6 months ago, respectively. 293 294 For the use in vaccination studies quantification of the T-cell response must be reliable. We were able 295 to show significant differences between the first and the second vaccination among groups as well as Limitation for the use of such a biological assay is the functionality of the T-cell response. Even low-308 dose steroid treatment may interfere with IGRA testing, as has been shown for Quantiferon TB in 309 immunocompetent children (34). We have seen in one of our patients that even short-term steroid 310 treatment may be of relevance. The patient yielded a negative mitogen control and a negative 311 response to SARS-CoV-2 antigen (46 and 15 mIU/ml) three weeks after vector/mRNA heterologous 312 vaccination, but SARS-CoV-2 S1-IgG was detectable. She was on high dose steroids when blood was 313 drawn, but not during vaccination. After stopping steroid treatment, we repeated the assay and 314 detected 985 mIU/ml after antigen stimulation with high positive mitogen control (1880 mIU/ml). 315

Further, the interpretation of grey-zone results is always difficult, so we developed a double cut-off 316 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.17.21260316 doi: medRxiv preprint 13 strategy including BLANK results in result interpretation. Diagnostic test accuracy analysis showed best 317 accuracy with similar negative predictive values using our adopted cut-off strategy. 318

In conclusion, the EUROIMMUN IGRA is an easy to perform assay for the detection of specific T-cell 319 response against SARS-CoV-2 spike antigen. The assay is highly specific and sensitive. During a 320 performance evaluation of the assay we were able to show that patients on immunosuppressive 321 regimens may have isolated T-cell or antibody response or in several cases do not respond at all. For 322 clinical practice, we recommend asking for steroid treatment before performing such an assay and if 323 possible pausing treatment before drawing blood. We propose that measurement of immune 324 response to vaccination should always include an analysis of the T-cell response and the EUROIMMUN 325 IGRA proved to be highly suitable for this purpose. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.17.21260316 doi: medRxiv preprint Table 5 . Combined immune response (detection of SARS-CoV-2 S1-IgG and/or IFN-y response) to 479 vaccination in immunocompromised patients and healthy adults. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.17.21260316 doi: medRxiv preprint

Postvaccination SARS-CoV-2 infections among skilled 376 nursing facility residents and staff members

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Virological surveillance of influenza viruses in the 381 WHO European Region in 2019/20 -impact of the COVID-19 pandemic

Assays up to Eight Months Post-COVID-19 Diagnosis

Early Experience with SARs-385

CoV-2 mRNA Vaccine Breakthrough Among Kidney Transplant Recipients

Cellular Immunity in COVID-19 Convalescents with

Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG

Discordant neutralizing antibody and T cell responses 390 in asymptomatic and mild SARS-CoV-2 infection

Adaptive immunity to SARS-CoV-2 and COVID-19

AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older 366 adults in England: test negative case-control study. BMJ 2021; 373:n1088. 367 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 22, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.17.21260316 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.17.21260316 doi: medRxiv preprint